Collaborating with OncoSpherix
OncoSpherix foresees a brighter future for patients with advanced cancer by combining our dual HIF inhibitors with agents that synergize to improve tumor control.
Our ongoing preclinical studies are testing combinations that include cytotoxic chemotherapy, targeted therapies, and immunotherapies. Our goal is to identify combinations that lead to the best tumor control with the least toxicity in order to improve quality of life and survival for patients with advanced cancer.
We welcome opportunities to partner with academic institutions, government agencies, pharmaceutical companies and other cutting edge biotechnology companies to test promising agents in combination with our dual HIF inhibitors in appropriate preclinical models. We also welcome opportunities for testing new drug delivery vehicles, tumor tracking methods and other promising technologies that complement our dual HIF inhibitors.
Intellectual property
OncoSpherix has an exclusive license from Emory University and Georgia State University to develop compounds that are protected by two US patents and international counterparts.
U.S. Patent # 9,062,072:
“Inhibitors of HIF-1 and angiogenesis” Active until 2031, not including patent term extension.
U.S. Patent #10,772,858:
“Benzhydrol derivatives for the management of conditions related to hypoxia-inducible factors”: Active until 2036, not including patent term extension.
Additional Patents:
Applications are in process.
Recent Corporate Events
OncoSpherix appointed Dr. Robert Scott to the Board of Directors in January 2021. Dr. Scott has held leadership positions in global Pharma for over thirty years, most recently as the Chief Medical Officer at Abbvie where he had responsibility for around 40 new molecular entities, four thousand people and a budget of close to two billion dollars. (learn more)
OncoSpherix appointed Mr Kenneth Moch as Special Advisor to the CEO in January 2021. Mr. Moch has more than 35 years of experience in managing and financing biomedical technologies. He was president and CEO of five life science companies—Cognition Therapeutics, Inc, Chimerix, Inc, BioMedical Enterprises, Inc., Alteon, Inc., and Biocyte Corporation. (learn more)